20/20 Onsite

01/17/2026

Iteration is not a phase. It is the operating system.

In this recent Forbes article, our CEO, Sonali Bloom, breaks down why continuous iteration is the only sustainable way to build, scale, and modernize complex industries.

When iteration is embedded into how teams work, not bolted on after failures, organizations move faster, waste less, and adapt before disruption forces their hand.

Read the full piece on Forbes and see how iteration becomes a daily discipline, not a reactive fix.

https://hubs.ly/Q03-Nm5R0

01/16/2026

Hybrid clinical trials sound flexible on paper.

When ocular endpoints are involved, not every assessment has to occur at the site.
And not every visit can be pushed remote without risk.

What we’re seeing across trials:
• Data variability increases when visit ownership is unclear
• Patient burden rises when travel-heavy visits are misallocated
• Sites lose time coordinating off-site referrals and rework

The fix is not “more hybrid.” The fix is a smarter visit split.

In this blog, we break down:
• Which ophthalmic assessments should stay centralized
• Which visits are best delivered at the point of need
• How to protect endpoint integrity without slowing enrollment

Hybrid only works when strategy is intentional.

Read the full breakdown here:
https://hubs.ly/Q03Ztvt50

01/14/2026

Build the team. Own the pipeline. Protect trial outcomes.

20/20 Onsite is hiring a Sales Manager in Everett, MA to lead and scale our commercial efforts supporting clinical trials. This role sits at the center of growth, accountability, and ex*****on.

You will run and forecast the pipeline, coach and develop a high-performing sales team, and assist with closing strategic opportunities. You will guide deals from discovery through contract.

What you bring:
+ 5+ years of B2B sales experience
+ 2+ years leading and coaching sales teams
+ Life sciences, clinical trials, or CRO experience strongly preferred
+ Comfort selling into complex, regulated environments

Transform patient access. Lead with accountability. Set the pace for trial success.

Apply here: https://hubs.ly/Q03-NR_w0

01/13/2026

Go behind the scenes with Wes Stuart, Optometric Technician, and Natasha Gass, Clinic Manager at 20/20 Onsite and see what mobile optometry looks like, from setup to closeout.

No scheduling headaches, no commute. Just quality eye care that fits into the workday.

And for clinical research teams, this same model can make a real difference, bringing protocol-required eye assessments to participants where they already are, reducing travel burden, and helping protect timelines and data completeness.

Bringing vision services to your team, or building a trial with ocular endpoints?

01/08/2026

Beyond clinical trial excellence, we're on a mission to close vision care gaps for students nationwide.

The gap between students and vision care isn't closing on its own. Traditional approaches leave too many families facing barriers: transportation challenges, scheduling conflicts, and limited access to optometrists. The result? 70% of students at our Orlando event needed glasses, nearly triple the national average.

Our school-based mobile clinic model changes everything.

📊 Advanced diagnostic technology on site
📊 Certified optometric staff at the school
📊 Comprehensive exams
📊 Follow-up care coordinated for every referral

The Orlando event validated what we've proven everywhere: when you bring vision care directly to students, outcomes transform. Teachers told us the mobile clinic turned routine exams into memorable learning experiences, sparking school-wide conversations about vision health.

The model works. The impact is measurable. The scalability is ready.

We're expanding our Schools Program and seeking funding partners, community collaborators, and school districts committed to ensuring every child has access to the care they deserve.

👉 Learn how we're scaling equitable eye health access: https://hubs.ly/Q03VS4350

Follow 20/20 Onsite for more vision health innovation in action.

01/06/2026

“We thought one or two missed visits wouldn’t matter...”

But by mid-trial, those small misses add up.
📊 At a median of $3,562 per patient visit (PubMed) — before considering lost data and extended timelines.

The truth is, inefficiency doesn’t show up as one big mistake.
It’s the silent drip of reschedules, travel hurdles, and unplanned drop-offs.

At 20/20 Onsite, we close that gap.
Our mobile vision clinics bring exams directly to patients — eliminating travel barriers and ensuring every scheduled visit gets completed.

Because in trials, precision isn’t just scientific - it’s financial.

Complete visits. Maximize value.

01/06/2026

The data’s clear, when you put patients first, success follows.

📊 Patient-centric trials see 87% launch success vs. just 68% for traditional models (Biopharma Dive).
That’s not luck. It’s access, convenience, and trust.

At 20/20 Onsite, we’ve built our model around the patient. Bringing advanced mobile vision care directly to communities nationwide.
Less travel. Less dropout. More engagement from start to finish.

When patients stay in, studies stay on track, and therapies reach the market faster.

Choose patient-centric care. Reach the market faster.

01/05/2026

Ivan Dario Quiroz, VP of Clinic Operations at 20/20 Onsite, sees this pattern constantly: trials lose participants when access is hard.

Not because people stop believing in the research. Because life gets in the way, work schedules, transportation, caregiving, and the friction adds up.

The cost is real:
- Industry dropout rate: ~30%
- Thousands in replacement cost per participant
- Timelines slip when re-enrollment starts

20/20 Onsite flips the model. We deploy Mobile Vision Clinics to where participants already are, workplaces, community locations, weekends, early mornings, whatever removes the barrier.

The result: 91% retention and fewer gaps in endpoint datasets.

Watch Ivan break down how accessibility becomes part of the protocol, not an afterthought. When you remove friction, participants stay enrolled. When participants stay enrolled, research moves forward.

At 20/20 Onsite, accessibility isn’t a perk. It’s built into every deployment.

01/03/2026

A practical way to build a future trial recruitment engine, without waiting on sites to “find” patients.

This case study lays out how point-of-need screening can translate to recruitment with minimal adjustments:

+ Layer trial pre-screen questions into community events
+ Capture consent for research follow-up and build a registry
+ Route qualified patients to trial sites or virtual pre-screen hubs
+ Repeat in priority geographies (senior centers, housing communities, high-yield locations)

If your study is vulnerable to slow enrollment, screen-fail spikes, or access barriers, this model helps you expand the diagnosed pool earlier and engage patients where trust already exists.

And when you need point-of-need ophthalmic assessments delivered with certified staff and validated equipment, that’s exactly what 20/20 Onsite is built for.

Read the full case study: https://hubs.ly/Q03Y8r-30

20/20 Onsite’s early disease detection for future trial enrollment pilot delivered mobile eye screenings—22% referred—proving a scalable, partner-agnostic model for early detection and trials.

01/01/2026

Happy New Year! 🎆

Here’s to a fresh start, new opportunities and continued collaboration in the year ahead. Wishing you health, happiness and success in 2026.

12/30/2025

Sonali Bloom, our CEO, was featured in a Forbes Business Council piece on “20 Company Practices To Retire By Year-End”

Her callout hit home because it’s a shift we’re actively making going into 2026:

“Historically, we have operated separate divisions or P&Ls. Starting in the new year, we’re adopting ‘one team, one dream’, as cheesy as that sounds. Cross P&L collaboration and bringing skill sets and mindsets from one practice to another has yielded big wins in 2025. Going forward, we’ll maximize this by bringing our leaders, teams and processes even closer together.”

If you’re planning for 2026 right now, this is a simple but powerful question to ask:
Where are we unintentionally creating friction by running in silos?

What’s one “company practice” you’re retiring before year-end?

Read the full article here: https://hubs.ly/Q03YX_4H0